$11 Bln Windfall From Consumer Spin-Off Expected For GSK’s Drugs Arm
Plans for transforming its consumer healthcare business into a separately listed company were revealed by GSK on Wednesday which would help the firm to further strengthen the process of drug development at the pharmaceuticals business unit of the company and have an 8 billion pound ($11 billion) windfall. It was in December 2018 that the…









